Evidence map›Paper›PMID 28642642›Full record

ArticleSubstance abuse : research and treatment2017

Access to and Payment for Office-Based Buprenorphine Treatment in Ohio.

Theodore V Parran, Joseph Z Muller, Elina Chernyak, Chris Adelman, Christina M Delos Reyes, Douglas Rowland, Mykola Kolganov

Open access · goldAbstract read
In one paragraph

Article in Substance abuse : research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Pharmacists and opioid use disorder care during COVID-19: Call for action.Journal of the American College of Clinical Pharmacy : JACCP · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Disparities in Opioid Use Disorder Treatment Admissions.Journal of health economics and outcomes research · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Theodore V ParranSchool of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Joseph Z MullerSchool of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Elina ChernyakUniversity Hospitals Health System, St. Vincent Charity Medical Center, Cleveland, OH, USA.
Chris AdelmanUniversity Hospitals Health System, St. Vincent Charity Medical Center, Cleveland, OH, USA.
Christina M Delos ReyesSchool of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Douglas RowlandSchool of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Mykola KolganovUniversity Hospitals Health System, St. Vincent Charity Medical Center, Cleveland, OH, USA.
St. Vincent Charity Hospital · USCase Western Reserve University · USUniversity Hospitals Case Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceOffice-based opiate agonist therapy has dramatically expanded access to medication-assisted treatment over the past decade but has also led to increased buprenorphine diversion.

objectiveOur study sought to characterize physicians who participate in office-based therapy (OBT) to assess patient access to OBT in Ohio 10 years after its introduction. DESIGN/SETTING/

participantsCross-sectional telephone survey of Drug Addiction Treatment Act-waivered physicians in Ohio listed by the Center for Substance Abuse Treatment (CSAT). MAIN OUTCOMES: This study sought to determine what proportion of eligible physicians are actively prescribing buprenorphine, whether they accept insurance for OBT, and whether they accept insurance for non-OBT services. In addition, we evaluated what physician characteristics predicted those primary outcomes. We hypothesized that a significant minority of eligible physicians are not active prescribers of buprenorphine. In addition, we expected that a significant minority of OBT prescribers do not accept insurance, further restricting patient access. We further hypothesized that a large subset of OBT prescribers accept insurance in their regular practices but do not take insurance for OBT.

resultsOf the 466 listed physicians, 327 (70.2%) practice representatives were reached for interview. Thirty-three physicians were excluded, with a true response rate of 75.5%. In total, 80.7% of providers reached were active OBT prescribers. Of these, 52.7% accepted insurance for OBT, 20.8% accepted insurance for non-OBT services but not for OBT, and 26.5% did not accept insurance for any services. Practices who did not accept insurance were more likely among dedicated addiction clinics located outside of Ohio's 6 major cities. Practices who normally accepted insurance but did not for OBT services were more likely in urban locations and were not associated with dedicated addiction practices. Neither business practice was associated with physician specialty. CONCLUSIONS AND RELEVANCE: Access to OBT in Ohio is far lower than what the 466 listed physicians suggests. Nearly 1 in 5 of those physicians are not active OBT prescribers, and 1 in 2 active prescribers do not accept insurance for OBT. Further research is needed to determine whether practices who do not accept insurance provide care consistent with CSAT guidelines and whether such practice patterns contribute to buprenorphine diversion.

Indexed as

Buprenorphinebuprenorphine accessinsurance coveragepayment and office-based treatment

Identifiers

PMID28642642
PMCPMC5473522
OpenAlexW2625807784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.